The Website uses cookies. By continuing to use this website, your consent to our use of these cookies. Find out more

Currency EUR
  • EUR
  • USD
IMMUNITRACK
Menu Search My Account
Cart
You have no items in your shopping cart.
  • My Account
  • Log In
  • Sign Up

Currency EUR
  • EUR
  • USD
IMMUNITRACKIMMUNITRACK
Menu
  • Reagents
    • MHC/Peptide Complex Overview
    • MHC I Reagents
    • MHC Allele Library
    • FcRn Molecules Overview
    • FcRn Reagents
    • FcRn Platform Compatibility
  • Technologies
    • NeoScreen Binding Assays
    • NeoScreen Technology
    • TCR-Like Antibodies
    • T Cell Identification
  • Application
    • Immuno-oncology
    • Vaccines
    • TCR Off-Target
    • Deimmunisation
  • News
  • Webshop
    • FcRn
  • About
  • Contact
  • Home
  • TCR-Like Antibodies

TCR-Like antibodies (TCR-LA) also known as TCR-mimic

Immunitrack has established a platform to develop and characterize TCR-LA (T cell receptor-like antibodies).

Conventional monoclonal antibodies (mAb) and chimeric antigen receptor (CAR) T cell therapies are the most successful strategies in cancer immunotherapy so far. However, these current modalities target proteins expressed on the surface of tumour cells, which comprise a limited repertoire of cellular proteins.

A New Avenue for Cancer Treatment

As an alternative TCR-therapies are under development, which enable the targeting of large repertoire of intracellular antigens that are displayed on the cell surface by MHC (Major Histocompatibility Complex). These therapies have on the other hand the disadvantage of cross-reactivity since TCRs are naturally promiscuous. TCR-LAs are a new avenue for cancer treatment by combining the advantages of mAbs with the TCR-like tumour target recognition.

Moreover, TCR-LAs are versatile and can therefore be engineered to a plethora of therapeutic formats such as CAR, ADC (antibody drug conjugate) and Bi-specific T-cell engager formats, among others.

Workflow – development of a TCR-LA

The workflow for early preclinical development of a TCR-LA comprises 7 steps:

  1. Selection of a tumor target based on its exclusive and abundant expression on tumour cells.
  2. Selection of an immunogenic epitope within the protein target.
  3. Production of highly pure and stable MHC-epitopes complexes for positive selection and negative selection.
  4. TCR-LA discovery using antibody technology or vendor of choice
  5. Off-target specificity studies on MHC-epitope complexes for TCR-LA clone selection – this is mostly done by ELISA.
  6. On-target specificity studies on model cell lines for TCR-LA clone selection- this is mostly done by flow cytometry analysis.
  7. Selection of TCR-LA clones based on effector properties – ex cell based cytotoxic assays (this depends on the antibody format being tested).

The different steps of TCR-LA platform comprise very specific technologies, and we at Immunitrack are specialized in the following ones:

Step 2. We can run NeoScreen assays in high-throughput mode with dozens of MHC alleles and hundreds of peptides simultaneously; this is a powerful and unique technique that allows to discover the most immunogenic epitope within a protein target.

Step 3. We can produce highly pure and stable MHC-peptide complexes from a large library of MHC molecules; for each antibody library screen we produce complexes for positive selection – and recommend a mixture if MHC complexes for negative selection.

Step 5. and 6. We have developed a series of on-target and off-target specificity assays for TCR-LAs, both for screening a high number of unrelated on MHC-peptide complexes and on peptide-loaded model cell lines. We can perform positional scanning assays, alanine and glycine scans and melting assays. Using our thorough specificity assays we are able select very specific TCR-LAs with limited risk of cross-reactivity.

Application Note

In this application note you will find a short description of our TCR-LA platform

Download Application Note

Contact Immunitrack

Don't hesitate to contact us to learn how we can help you to define immunogenic epitopes and identify specific T cell responses.

Please contact us on phone, or by email to info@immunitrack.com

Tel. +45 28682159

TCR-LA Links

  • Application: Immuno-oncology ▸
Subscribe
About us

Immunitrack’s mission is to provide the research community with tools to select or redesign drug candidates at the early stage of R&D but also to provide reagents to monitor lead drug candidates effect on patient’s immune system.

Contact

Immunitrack ApS
Lersø Parkallé 42
2100 Copenhagen Ø
CVR: 32347908

info@immunitrack.com
Tel. +45 28682159

Legal
  • Terms and conditions
  • Privacy statement
  • Legal notice and disclaimer
Follow us
Privacy Policy
×
This is the privacy policy sample page.
It was created automatically and do not substitute the one you need to create and provide to your store visitors.
Please, replace this text with the correct privacy policy by visiting the Customers > GDPR > Privacy Policy section in the backend.
I have read and accept